Ignite Creation Date:
2025-12-24 @ 3:17 PM
Ignite Modification Date:
2026-02-02 @ 12:04 PM
Study NCT ID:
NCT04055792
Status:
COMPLETED
Last Update Posted:
2023-06-28
First Post:
2019-08-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC
Sponsor:
Henan Cancer Hospital
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Extensive Disease Small Cell Lung Cancer | View |